SEC FILE NUMBER
001-35141

CUSIP NUMBER 759757 867

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### **FORM 12b-25**

NOTIFICATION OF LATE FILING

$(Check\ one): \boxtimes \text{ Form } 10\text{-K} \sqcup \text{ Form } 20\text{-F} \sqcup \text{ Form } 11\text{-K} \sqcup \text{ Form } 10\text{-Q} \sqcup \text{ Form } N\text{-CEN} \sqcup \text{ Form } N\text{-CSR}$					
For Period Ended: <u>December 31, 2023</u>					
☐ Transition Report on Form 10-K					
☐ Transition Report on Form 20-F					
☐ Transition Report on Form 11-K					
☐ Transition Report on Form 10-Q					
For the Transition Period Ended:					
Read Instruction (on back page) Before Preparing Form. Please Print or Type.					
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.					
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:					
PART I — REGISTRANT INFORMATION					
Rennova Health, Inc. Full Name of Registrant					
Former Name if Applicable					
400 South Australian Avenue, Suite 800 Address of Principal Executive Office (Street and Number)					
West Palm Beach, FL 33401 City, State and Zip Code					

#### PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

(a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

×

- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

#### PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Rennova Health, Inc. (the "Company") is unable to file, without unreasonable effort and expense, its Annual Report on Form 10-K for the year ended December 31, 2023 within the prescribed time period because the Company is still compiling information for the Form 10-K and its auditors have not completed their audit of the financial statements for the year then ended. The Company expects to file its Form 10-K on or prior to the fifteenth calendar day following the prescribed due date.

Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(Attach extra Sheets if Needed)

	PART IV — OTHER INFORMATION				
(1)	Name and telephone number of person to contact in re-	gard to this notification			
	Seamus Lagan	561	855-1626		
	(Name)	(Area Code)	(Telephone Number)		
(2)	1 1 1	13 or 15(d) of the Securities Exchange Act of 1934 or Sectice registrant was required to file such report(s) been filed? If a	1 3		
(3)	Is it anticipated that any significant change in results of included in the subject report or portion thereof?	of operations from the corresponding period for the last fisc	cal year will be reflected by the earnings statements to b ${\rm Yes} \; \square  {\rm No} \; {\color{black} \mathbb{E}}$		
	If so, attach an explanation of the anticipated change cannot be made.	e, both narratively and quantitatively, and, if appropriate, st	tate the reasons why a reasonable estimate of the result		
		2			

## Rennova Health, Inc. (Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date	April 1, 2024	By	/s/ Seamus Lagan
			Seamus Lagan
			Chief Executive Officer
	3		